New Biosimilar Product to Humira Could Be Cheaper and Just as Effective for Ankylosing Spondylitis Patients

The most common treatment for autoimmune conditions such as ankylosing spondylitis, plaque psoriasis, Crohn's disease, juvenile idiopathic arthritis, and rheumatoid arthritis is currently a drug called Humira, created by AbbVie.…

Continue Reading New Biosimilar Product to Humira Could Be Cheaper and Just as Effective for Ankylosing Spondylitis Patients

A Record Number of FDA Drug Approvals in 2018 Is Followed by an Encouraging Start for 2019

Following a record number of approvals in 2018, the FDA has recently approved two new drugs with many more anticipated approvals later in the year. Trazimera to Treat Human Epidermal…

Continue Reading A Record Number of FDA Drug Approvals in 2018 Is Followed by an Encouraging Start for 2019
The Challenges Faced by Those Affected by PFIC Highlighted on Rare Disease Day
source: pixabay.com

The Challenges Faced by Those Affected by PFIC Highlighted on Rare Disease Day

According to a story from Financial Buzz, the biopharmaceutical company Albireo Pharma, Inc. issued a statement on Rare Disease Day which emphasized the company's continued commitment to progressive familial intrahepatic…

Continue Reading The Challenges Faced by Those Affected by PFIC Highlighted on Rare Disease Day